Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster.
The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website.
By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.
Re: BMJ. The truth about Tamiflu? Data access is matter of trust.
Letters
The truth about Tamiflu?
Data access is matter of trust
The UK Faculty of Public Health strongly supports the BMJ?s<sup> </sup>call for mandatory disclosure of raw data of all trials cited<sup> </sup>in drug licensing applications and marketing claims.<sup>1</sup><sup> </sup>
We see this as a first step towards a position in which only<sup> </sup>external independent trials published in peer reviewed journals,<sup> </sup>with full access to raw data, should be allowable when seeking<sup> </sup>a licence or marketing a product. This would require international<sup> </sup>agreement by health technology regulators.<sup> </sup>
Interpreting the evidence base for healthcare planning and commissioning<sup> </sup>is a key public health function. Full disclosure and openness<sup> </sup>to scrutiny of evidence on efficacy and safety are crucial if<sup> </sup>the pharmaceutical industry is to maintain the full trust and<sup> </sup>confidence of patients, practitioners, policy makers, and the<sup> </sup>wider public.
